Galactoarabino-rhamnogalacturonate: Phase II started

Galectin began the double-blind, placebo-controlled, U.S. Phase II NASH- FX trial to evaluate 8 mg/kg GR-MD-02 every 2 weeks for 16 weeks in 30 patients. ...